Aprea Therapeutics (NASDAQ:APRE) Stock Rating Upgraded by Zacks Research

Aprea Therapeutics (NASDAQ:APRE) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other brokerages have also recently commented on APRE. Wedbush lowered their target price on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, February 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, January 21st. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 target price (down from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Aprea Therapeutics has a consensus rating of “Hold” and a consensus price target of $5.50.

Aprea Therapeutics Trading Down 1.5%

Shares of NASDAQ APRE opened at $0.60 on Monday. The company’s 50-day moving average price is $0.83 and its 200 day moving average price is $1.22. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $3.72. The stock has a market cap of $4.19 million, a price-to-earnings ratio of -0.28 and a beta of 1.48.

Insider Activity

In related news, Director Marc Duey purchased 21,459 shares of the business’s stock in a transaction on Wednesday, December 10th. The shares were bought at an average price of $1.17 per share, with a total value of $25,107.03. Following the completion of the purchase, the director directly owned 256,155 shares in the company, valued at approximately $299,701.35. This trade represents a 9.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 13.63% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned approximately 1.73% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.